Sale!

Retatrutide – 5mg | 10mg

$119.99$199.00

5/10 mg per vial

Add to Wishlist
Add to Wishlist
FREE & FAST SHIPPING
PUREST QUALITY
EXCELLENT SERVICE

Properties

Molecular Formula

C221H342N46O68

Molecular Weight 4845.444
Monoisotopic Mass
Polar Area
Complexity
XLogP
Heavy Atom Count
Hydrogen Bond Donor Count
Hydrogen Bond Acceptor Count
Rotatable Bond Count
Physical Appearance Fine White Lyophilized Powder
StabilityLyophilized protein is to be stored at -20°C. It is recommended to aliquot the reconstituted (dissolved) protein into several discrete vials in order to avoid repeated freezing and thawing. Reconstituted protein can be stored at 4°C
PubChem LCSS

Thymalfasin Laboratory Chemical Safety Summary

Identifiers

CID
CAS2381089-83-2
InChI
InChIKey
Isomeric SMILES
Canonical SMILES
IUPAC Name

Description

NuScience Peptides sells research products only, they are not for human consumption.

Retatrutide – Description

Retatrutide is a novel investigational peptide being explored for its potential therapeutic benefits in metabolic disorders, particularly obesity and type 2 diabetes. It is a multi-receptor agonist that targets multiple pathways involved in glucose and energy homeostasis. Here’s a detailed description of retatrutide for research purposes:

Key Features and Mechanism of Action

  1. Multi-Receptor Agonist: Retatrutide is designed to activate multiple receptors, specifically the glucagon-like peptide-1 (GLP-1) receptor, the glucagon receptor, and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This multi-receptor approach aims to leverage the synergistic effects of these pathways on metabolism.
  2. GLP-1 Receptor Activation: GLP-1 is an incretin hormone that enhances insulin secretion in response to food intake, inhibits glucagon release, and slows gastric emptying. Activation of the GLP-1 receptor helps improve glycemic control and promotes satiety, leading to reduced food intake.
  3. Glucagon Receptor Activation: Glucagon increases energy expenditure and promotes weight loss by enhancing hepatic glucose production and lipolysis. This contributes to the overall metabolic effects of retatrutide.
  4. GIP Receptor Activation: GIP enhances insulin secretion and has anabolic effects on adipose tissue. The combination with GLP-1 receptor activation aims to optimize insulinotropic effects and weight management.

Research Applications

  1. Obesity and Weight Management: Retatrutide’s ability to reduce appetite and increase energy expenditure makes it a promising candidate for studying obesity. Animal studies and early-phase clinical trials focus on its effectiveness in inducing weight loss and improving metabolic parameters.
  2. Type 2 Diabetes: By enhancing insulin secretion and improving glycemic control, retatrutide is being explored as a treatment for type 2 diabetes. Its multi-receptor action potentially offers superior glucose-lowering effects compared to single-receptor agonists.
  3. Metabolic Syndrome: Retatrutide is of interest for its potential to address various components of metabolic syndrome, including hyperglycemia, dyslipidemia, and hypertension, through its comprehensive metabolic effects.
  4. Liver Diseases: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are being studied in the context of retatrutide’s ability to reduce liver fat and improve liver function markers.

Preclinical and Clinical Research

  1. Animal Studies: Preclinical studies in rodent and non-human primate models have shown that retatrutide effectively reduces body weight, improves insulin sensitivity, and lowers blood glucose levels. These studies also indicate beneficial effects on lipid metabolism and liver fat reduction.
  2. Clinical Trials: Early-phase clinical trials have demonstrated promising results in humans, with significant weight loss and improved glycemic control observed in participants. Ongoing trials are focused on optimizing dosing regimens and further evaluating the safety and efficacy profile

Conclusion

Retatrutide represents a promising multi-receptor agonist peptide for treating metabolic disorders, particularly obesity and type 2 diabetes. Its comprehensive approach to enhancing glycemic control and promoting weight loss through GLP-1, glucagon, and GIP receptor activation makes it a valuable subject of ongoing research. Continued studies are essential to fully understand its therapeutic potential and safety profile, paving the way for potential clinical applications in managing metabolic diseases.

NuScience Peptides sells research products only, they are not for human consumption.

Reference:

Pubmed

ALL LITERATURE, INFORMATION, AND DATA, PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

BPC157 Peptide

Accurate research is our number one priority.

Same Day Shipping

Enjoy the convenience of receiving your order swiftly. We offer same-day shipping on all orders of in-stock items placed before 12:00 pm EST.

Dedicated Service

Our dedicated team is always at your service, Ready to assist you with any customer service requests you may have. We prioritize your satisfaction and aim to provide a seamless experience.

Free Shipping

To enhance your shopping experience, We offer free shipping on all orders totaling $200 or more. Rest assured, we've got you covered!

Purist Quality

We take pride in ensuring the utmost purity of our products. Every item we offer undergoes rigorous lab testing and is certified for the highest possible purity.

Shopping cart

0
image/svg+xml

No products in the cart.

Continue Shopping